

You're receiving this email because you are part of the EurocanPlatform project. Please add claire@ecancer.org to your address book so this newsletter will land in your inbox.

You may [unsubscribe](#) if you no longer wish to receive our emails.



Quick Links

[Project website](#)

[Intranet](#)

Here are the the latest project updates and announcements:

Upcoming Meetings

- **WP1:** SSC and ExeCo meeting **10th September** in Amsterdam
- **Personalised Cancer Care Symposium:** 7-9th September, Holmenkollen Park Hotel, Oslo. Click [here](#) for more information.
- **Symposium on Pre-Clinical Assays in Cancer Therapy** (NKI and Institut Curie): **26-28th September**. Click [here](#) for more details.
- **WP2: Expert group meeting on 'two way translational cancer research: an opportunity for cancer control'**, 16-17th October. View full details [here](#).
- **WP11:** 20th September meeting has been cancelled and replaced by 9th October. Meeting location is to be confirmed in invitations, which will be sent out by WP11.
- **2nd Annual Meeting: 5-6th December**, Netherlands Cancer Institute, Amsterdam. An email has been sent to the project mailing list with details about hotel registration. Participants need to arrange travel and accommodation for themselves. If you have questions about the meeting, please contact [Christina](#).

WP activities

- **WP11** has sent out a new proposal on colorectal cancer, asking partners to sign up if they wish to participate. Contact [Adam Gondos](#) for information.
- EurocanPlatform will perform a clinical effectiveness study of anticancer agents within **WP11**. The suggestion is to start with metastatic breast cancer. Partners who wish to participate in this study

are asked to send the name and contact details of a person who will take part in the work on behalf of your institute/organisation to Christina.von.Gertten@ki.se

- A decision was made at the Project Steering Committee meeting in Berlin this year to start building a structure for research outcomes (**WP11**). Please provide the name and contact details of a person who will commit and work on behalf of your institute/organisation in the build-up to Christina.von.Gertten@ki.se

- A **reminder** for Partners who have not yet provided a contact for the development of **Molecular Pathology** within the network to do so asap if they wish to participate. Please email Christina.von.Gertten@ki.se. A meeting will be arranged as soon as all names have been collected.

EurocanPlatform video content from EACR-22: 'Translational and tailored, but can we afford it?' satellite symposium

During the July EACR-22 Congress in Barcelona, EurocanPlatform, in partnership with *ecancer* and Vall d'Hebron Institute of Oncology, presented the 'Translational and tailored, but can we afford it?' satellite symposium.



Professor Richard Sullivan

The symposium presentations are interviews are now live on the project [website](#) and on ecancer.org

The symposium was awarded 2 European Continuing Medical Education Credits (ECMEC) by the European Accreditation Council for Continuing Medical Education and approved by the Accreditation Council of Oncology in Europe (ACOE).

Associate project partner

McGill University in Quebec, Canada, will become an associate partner to the EurocanPlatform project.

European Commission project issues

- A second amendment has been sent to the EC concerning a work

change in WP7

- The revised P1 report has been sent to the EC. The project coordinators are now waiting on a response.

News and updates wanted from YOU!

We would like to encourage participants to send in information about their past, present and future Platform activities.

The more information we receive, the more we can update the whole consortium about all the hard work you are doing!

A template will be set up in the Platform [Intranet](#) to facilitate the process. More information on this to follow.

Forthcoming deliverables

Deliverables due in **month 24**:

- 1.4** - Evaluation of exchange programme for researchers
- 2.4** - Expert group meeting on 'Research needs for evidence-based guidelines on cancer screening'
- 2.7** - Consensus meeting on 'Contribution of molecular epidemiology to evidence-based developments'
- 4.1** - Inventory of kinase mutations in ovarian cancer
- 4.2** - Inventory of activated kinases in ovarian cancer identified by RPPA
- 4.3** - Copy number variation maps of ovarian cancer
- 6.4** - Methodology and statistical designs
- 7.3** - Biomarkers for BRCA positive human tumours
- 8.4** - A catalogue of technological resources available in the participating centres
- 9.1** - ECPE-tool for mapping genomic aberrations
- 9.2** - DCEC-tool for segmental copy-number detection
- 9.3** - Protocol for data collection, management and access system
- 9.6** - Report on conceptual approach for data integration
- 10.7** - Report on assessment of the standardisation, QA and QC to be implemented in the EurocanPlatform bio
- 10.13** - Implementation cooperation between population and clinical cancer biobanks
- 11.2** - Set of common data elements to be assessed at all sites (core and supplementary)
- 11.3** - Standardised review of institution specific resources
- 13.5** - Hold a forum for discussing and exchanging courses
- 14.4** - Platform to exploit tumour marker data
- 15.4** - Ethical midterm review

ecancer is here as a dissemination resource for all your news. For any press and media related issues, email claire@ecancer.org
You can also publish reports and papers that come out of the project in ecancermedicalscience for free. For information, email editor@ecancermedicalscience.com



This email was sent to claire@ecancer.eu by claire@ecancer.org | [Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

ecancer | 154 Cheltenham Road | Bristol | BS6 5RL | United Kingdom